The Magneto-Immune Therapy is the most effective elements of the CellAdam therapeutic system. It is based on the simultaneous application of the Celladam Cream and Celladam agents, respectively, together with the Magneto Therapy.
MIT is usually employed as a cure, but after clinical oncological treatment(s) also the continuous MIT is advisable. The minimal duration of the MIT is 2 months.
The basic aim of the development of MIT was its usability as a home therapy.
Use of the instrument and the therapy itself are simple enough to be done by unskilled family members after a short training.
One treatment a day is suggested. The Celladam Cream is applied to the back of the patient and he/she lays down with his/her back on the magentic pillow. In the beginning, 15-20 minutes should be set on the front control panel. Then, depending on the patient's temperature (an indirect indicator of the state of the immune system), the duration is set longer or shorter. At the expiration of the preset time, the instrument cuts out automatically, this being signalled by a short ring.
The efficiency of the therapy increases when the location of the tumor is diagnosed.
In this case, the Celladam Cream is applied directly over the location of the tumor, as diagnosed.
Applying the CellAdam drops will shift the 0.5 remission limit (where the cancerous process might still be considered reversible) by almost a full order of magnitude. In other words, in the case of 109 malignant cells (considered to be the end of the early stage), the malignant tumor can be healed with a probability of temission of 80%, as opposed to the original 50%.
The reversibility limit shifts more dramatically under the effect of the MIT and the early stage (106-109 deviant cells) is safely under control.
What can be considered "prevention" and what is the early stage?
Figure shows a remission curve displaying the probability of the re-establishment of the immune equilibrium vs. the number of deviant cells when no external intervention is applied.
The limit where an efficient immune system can provide the full remission can be estimated to be at the number of 106 deviant cells (cca.1 mg).
Prevention should ensure the number of deviant cells not to exceed 106. The range between 106 and 109 is considered the early stage of the cancerous process, while the range between 106 and 1012 is the category of advanced malignant tumors, the subject of modern clinical practice. This is a statistical approach to categorizing the phases of the development of the cancerous process.
